We did a cost-effectiveness analysis alongside a cluster-randomised trial of an intervention combining microfinance with gender and HIV training for the prevention of intimate-partner violence in South Africa. The average cost per client was $43 in the trial phase and $13 in the initial scale-up phase. On the basis of effect estimates from the trial, this translates to $711 and $213 per woman per IPV-free year gained. Using recent burden of disease estimates for intimate partner violence from South Africa, we estimated the cost per DALY gained as $7,700 for the trial and $2,307 for the initial scale-up. The findings were sensitive to the statistical uncertainty in effect estimates but otherwise robust to other key assumptions employed in the analysis. These estimates are probably conservative, as they do not include the health and development benefits of the intervention beyond IPV reduction. The findings suggest that this combined economic and health intervention was cost-effective in its trial phase and highly costeffective in scale-up.
Introduction
Physical and sexual violence against women in South Africa is a major challenge, with recent estimates suggesting nearly 25% of ever-partnered women report having been in an abusive relationship 1 . In addition to being an affront to women's rights, intimate partner violence is increasingly recognised as a neglected but important public health problem, with significant impacts on women's physical, reproductive and sexual, and mental health 2, 3 . The development of cost-effective interventions with the potential to prevent IPV and that are appropriate and relevant to resource poor settings, particularly in rural areas, remains an urgent priority. The microfinance (MF) component of the intervention offered access to group-based credit and savings services, using a Grameen Bank model, 6 where five women formed a solidarity group to collectively guarantee one another's loans. Forty women constituted a 'loan centre' which met fortnightly to repay loans and discuss financial matters. The programme was administered by Small Enterprise Foundation (SEF, Tzaneen, South Africa) and was poverty focused -targeting the poorest households in each village identified through participatory wealth ranking techniques 7 . Loans were used for income generation, with the most common types of businesses being buying and selling fruit and vegetables (54%), making/selling clothing (23%), food stalls (8%), and running small spaza shops a (5%).
a These are small shops in the local village that sell a wide variety of products, ranging from bread and soft-drinks to small household wares. Adjusted Life Years (DALYs). This enabled an assessment as to whether the type of activities incorporated in the approach can feasibly be built into the business models of microfinance organisations and importantly, whether such programs merit the allocation of scarce public funding through some form of subsidy. Finally, as access to the intervention in the post-trial period was substantially expanded and efforts were made to institutionalise the intervention within communities, we also examined the costs and cost-effectiveness of scale-up.
Methods
Trial costs were measured over the duration of the trial period during which the combined intervention package was delivered to 855 clients in four target villages. IPV outcomes were assessed after 2 years of intervention exposure. Costs associated with the scale-up were based on observed costs over the initial two years following the trial, and involved an additional 2598 clients. On the basis of the primary outcome of the trial, the costs of the intervention per additional woman free of IPV for the previous 12 months were estimated for both the trial and scale-up. These results were then transformed, on the basis of demographic 13 and burden of disease data from South Africa 14, 15 , into estimates of costs per DALY gained to enable a general assessment of costeffectiveness. The cost-effectiveness of IMAGE in the trial phase was thus estimated separately from the initial 2 years of scale-up.
Costs
The costing adopted an ingredients approach 16 Insert table 1 All items of capital (office space, equipment, vehicles) were assigned a current market/replacement value based on national South African prices at the base year (e.g. the estimated local prevailing market rent for office space) and cost allocated to the intervention on the basis of estimated use.
Personnel costs, valued either at prevailing gross salary in the relevant year or -for volunteer labour -at the market rates for equally qualified personnel occupying equivalent positions, reflecting their economic cost 18 . Other recurrent costs included supplies, transport and maintenance.
Costs associated with adherence to the research protocol were excluded 18, 19 . These were incurred because the sites chosen for the intervention were located substantially farther apart than would normally be the case due to random village assignment.
Adjustments to transport costs were therefore made by assuming the use of public transport by local staff in line with program operations in a non-research setting.
A major component of costs were the initial development costs associated with training of staff and production of training materials. As it was expected that the initial investment in these activities would yield benefits beyond the duration of the study, such costs were annuitised 16, 20 . Initial staff training was annuitised over 5 years, while conceptualisation of the protocol and production of the SfL training manuals was annuitised over 10 years to reflect their potential for use not only in scale-up but in other settings. Factored into these costs were consultancy services that were required for the planning of the initial intervention and in the training of staff and volunteers.
At the commencement of scale-up, further training was undertaken to enable expansion of the program. Major new inputs were the training and deployment of additional facilitators. Each trainer was responsible for nine loan centres, in line with standard practice for the microfinance partner. The cost of this training was annuitised in line with the approach used at the outset of the trial. Overall, the analysis of scale-up costs employed similar assumptions and methods as for the trial.
Effectiveness
The effectiveness of the intervention in terms of reduction in the risk of past year IPV as observed in the trial was assumed to apply to both the trial and the scale-up. Scale-up entailed the expansion of the intervention to populations in surrounding districts where we assumed the integrity and quality of the intervention was well-maintained. We would expect no difference in baseline characteristics between such similarly treatment-naïve trial and scale-up populations to thus suggest any difference in absolute effect.
The transformation of the primary trial outcome into DALYs is outlined in table 1. It was based on recent burden of disease estimates of DALYs lost to IPV in South Africa 14, 15 and population data 13 . It indicates that each case of a woman reporting an experience of IPV in the previous 12 months, on average, resulted in a loss of 0.0923 DALYs.
Insert table 1   Table 2 indicates the DALY loss from the specific conditions which were included as the relevant sequelae of IPV in the original burden of disease estimates. 15 
Insert table 2
Sensitivity analysis was conducted in relation to the following parameters:
• the upper and lower bound confidence limits of the effect estimates from the trial 5 • increasing the expected life of investment in staff training to 10 years;
• decreasing the expected life of investment in protocol development and training manuals to 5 years; and
• varying the discount rate to 0% and 6%
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. Table 3 sets out the development costs. These included the costs of training and training material development incurred initially, at the outset of the trial, and the further training costs at the commencement of the scale-up.
Results

Development costs
Insert table 3
The initial training costs were $61,115, the costs of training material development were $13,877, and further training costs at scale-up were $57,663. A significant component of the development costs at the initiation of the trial were consultant fees paid to overseas experts; these were not incurred in the scale-up since the training in the latter phase was carried out by local program staff. Table 4 reports a breakdown of cost figures for the duration of the trial and initial scaleup and cost-effectiveness estimates.
Cost-effectiveness
Insert table 4
Over the two-year trial period, the cost of SfL training was $36,706. In total, 855 clients participated in the intervention, with total per client costs equal to $43. During the initial scale-up, the total cost to reach an additional 2,598 clients was $33,467, with a cost per client of $13.
When set again effect estimates from the trial, cost-effectiveness ratios for the trial and the scale-up phase were $711 and $213 per woman per IPV-free year gained respectively. On the basis of the transformation outlined in table 1, these equate to $7,700 and $2,307 per DALY gained.
Sensitivity analysis
The sensitivity analysis in table 5 indicates:
• some uncertainty in relation to the effect estimates -a consequence of the limited number of clusters enrolled in the trial, resulting in wide confidence intervals for most indicators. For the trial, the cost per DALY ranged from $5,500
to $47,058; whilst for initial scale-up, it ranged from $1,648 to $14,099.
• the results were fairly robust in relation to the other parameters. Varying these results in cost-effectiveness between $5,015 to $8,193 for the trial phase and $1,454 and $2,503 for the initial scale-up.
Insert table 5
Discussion
The IMAGE intervention combined group-based microfinance with a gender and HIV , and emotional and psychological conditions including depression and anxiety (see table 3 ). Data on savings to the health sector associated with improvements in outcomes were not collected. While inclusion of such data would further support the case for cost-effectiveness, access to care for victims of IPV remains a serious obstacle in this population.
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. Nevertheless, generating estimates of disability-adjusted-life year (DALYs) attributable to IPV enabled the broader implications of violence to be factored into the assessment of outcomes in the economic evaluation.
The World Health Organization generalised benchmark for cost-effectiveness is that a cost per DALY of less than 3 times the gross domestic product per capita (GDP) is deemed 'cost-effective'; and that a cost per DALY of less than the GDP per capita is deemed 'highly cost-effective' 23 . In 2004, the GDP per capita in South Africa was $4,666 24 , indicating that the IMAGE intervention achieves cost-effectiveness in its trial phase and is highly cost-effective when scaled-up.
Additionally, it needs to be recognised that complex structural interventions such as IMAGE have the potential to influence multiple health and social outcomes. In such cases, cost-effectiveness might be more appropriately assessed through a costconsequences analysis in which the full range of benefits of the intervention are acknowledged 18, 20, 25 . In the trial, it was established that the intervention reduced poverty, led to positive shifts in social capital and multiple indicators of empowerment, and resulted in lower levels of HIV risk behaviour among young women who received the intervention 4, 5, 26, 27 . As such, the cost per DALY estimates presented here based solely on reductions in IPV are likely to underestimate the true value of the intervention.
There are also potential limitations to our estimates that are important to underscore.
First, the distinction between research-driven costs and operational costs were at times complex to disentangle. Close collaboration with the teams involved was crucial for the identification of the resources devoted to each activity, and of the rationale to discriminate operational and research-driven features of the trial period. Second, recall bias on the part of project staff had the potential to interfere with the accuracy of our assessment. However, we feel the adoption of a micro-costing approach yielded a very accurate assessment of resources used for the trial and initial phase of the scale-up. In addition, triangulation of data sources was used to check consistency, including multiple members of staff asked to relate the process of the intervention, the same pieces of information being collected from different individuals, and the information that individuals reported being checked against financial records where relevant.
Cost-effective interventions for the prevention of IPV in resource-poor settings are critically important, yet the evidence base to facilitate policy and program development remains at an early stage. This study indicates that coupling financial services to skills building and education may provide an important opportunity for addressing IPV.
Emerging evidence from the microfinance sector suggests such integrated approaches may lead to additional health benefits -including improvements in breast-feeding, diarrhoea management, immunisation rates, and the nutritional status of children 28-30 31-34 . This study suggests that proven development initiatives such as microfinance represent ideal opportunities for such value-adding public health interventions and that some form of public subsidy to support and strengthen these is warranted. Annuitised training costs -scale-up 13,520 
